Clinically, HR+ breast tumors can be effectively treated with endocrine-based therapies including aromatase inhibitors (AI), selective estrogen receptor modulators (SERMs), selective ER down-regulators (SERD) as well as gonadotropin-releasing hormone (GnRH) agonists [194]. The gene discussed is ESR1; the disease is breast neoplasm.